Independent clinical research site network hyperCORE International has collaborated with VirTrial for a training programme.
The collaboration will make hyperCORE the first ‘Virtual Trial Capable’ site network in the world.
Go deeper with GlobalData
hyperCORE has more than 80 sites across five countries and two continents.
hyperCORE International and Benchmark Research CEO Mark Lacy said: “hyperCORE International is a proponent of meaningful change in how clinical trials are delivered to patients, ensuring that efficiencies are realised.
“The benefit of having the network trained and certified on virtual trials provides sponsors the option to conduct decentralised clinical trials within an experienced site network where they can maintain control over quality and standardisation across sites.”
The training programme contains four modules that need to be completed by clinical research professionals to demonstrate a level of competence in general telemedicine etiquette and guidelines.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataParticipants will then be issued with a Virtual Trial Capable certificate and badge, which is used by sponsors and CROs to identify those who are prepared to conduct hybrid decentralised clinical trials.
VirTrial Business Development vice-president Amanda Rangel said that the company is taking a grass-roots approach to decentralised clinical trials by aligning with sites and helping them prepare to transform from traditional trials to hybrid trials.
hyperCORE International COO Jeff Kingsley said: “Direct to patient clinical trials are a massive benefit to our industry and to the patients who give so much of themselves to help us learn and advance.
“Patients will have an easier time committing to the rigors of a clinical trial knowing that they can participate from the comfort of their own home or work.”
